Key facts
- This page summarizes Douglas P. Golwas's Form 4 filing for Medline Inc. (MDLN).
- 8 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 06 Mar 2026, 16:50.
Douglas P. Golwas - 16 Dec 2025 Form 4 Insider Report for Medline Inc. (MDLN)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- MDLN
- Reported as of
- 16 Dec 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2026, 16:50:13 UTC
- Next SEC filing
- 17 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nicole Fritz, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Douglas P. Golwas filed Form 4 for Medline Inc. (MDLN) on 06 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002061504
Primary reporting owner
Golwas Douglas P
- Relationship
- Chief Commercial Officer
- Address
- C/O MEDLINE INC., 3 LAKES DRIVE, NORTHFIELD
- Signature
- /s/ Nicole Fritz, Attorney-in-Fact
- Signature date
- 06 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MDLN
transaction
Class B Common Stock
Award
- Transaction value
- Shares
- +465,864
- Change %
- Price
- Shares after
- 465,864
- Date
- 16 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2
MDLN
transaction
Class A Common Stock
Award
- Transaction value
- Shares
- +25,788
- Change %
- Price
- $0.000000*
- Shares after
- 25,788
- Date
- 05 Mar 2026
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MDLN
transaction
Derivative
Common Units of Medline Holdings, LP
Award
- Transaction value
- Shares
- +465,864
- Change %
- Price
- Shares after
- 465,864
- Date
- 16 Dec 2025
- Ownership
- See Footnote
- Underlying class
- Class A Common Stock
- Underlying amount
- 465,864
- Exercise price
- Footnotes
- F1, F4
MDLN
transaction
Derivative
Incentive Units of Medline Holdings, LP
Award
- Transaction value
- Shares
- +948,597
- Change %
- Price
- Shares after
- 948,597
- Date
- 16 Dec 2025
- Ownership
- See Footnote
- Underlying class
- Class A Common Stock
- Underlying amount
- 948,597
- Exercise price
- $15.42
- Footnotes
- F1, F5, F6, F7
MDLN
transaction
Derivative
Incentive Units of Medline Holdings, LP
Award
- Transaction value
- Shares
- +463,211
- Change %
- Price
- Shares after
- 463,211
- Date
- 16 Dec 2025
- Ownership
- See Footnote
- Underlying class
- Class A Common Stock
- Underlying amount
- 463,211
- Exercise price
- $15.42
- Footnotes
- F1, F5, F6, F8, F12
MDLN
transaction
Derivative
Incentive Units of Medline Holdings, LP
Award
- Transaction value
- Shares
- +212,755
- Change %
- Price
- Shares after
- 212,755
- Date
- 16 Dec 2025
- Ownership
- See Footnote
- Underlying class
- Class A Common Stock
- Underlying amount
- 212,755
- Exercise price
- $15.23
- Footnotes
- F1, F5, F6, F9
MDLN
transaction
Derivative
Incentive Units of Medline Holdings, LP
Award
- Transaction value
- Shares
- +157,800
- Change %
- Price
- Shares after
- 157,800
- Date
- 16 Dec 2025
- Ownership
- See Footnote
- Underlying class
- Class A Common Stock
- Underlying amount
- 157,800
- Exercise price
- $19.01
- Footnotes
- F1, F5, F6, F10
MDLN
transaction
Derivative
Incentive Units of Medline Holdings, LP
Award
- Transaction value
- Shares
- +149,005
- Change %
- Price
- Shares after
- 149,005
- Date
- 16 Dec 2025
- Ownership
- See Footnote
- Underlying class
- Class A Common Stock
- Underlying amount
- 149,005
- Exercise price
- $27.68
- Footnotes
- F1, F5, F6, F11
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 12 footnotes
Footnote F1
These securities were acquired in connection with the reclassification of the interests of Medline Holdings, LP prior to the Issuer's initial public offering (as more fully described in the Registration Statement on Form S-1). These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025.
Footnote F2
Shares of the Issuer's Class B common stock ("Class B Common Stock") have no economic value and have one vote per share. One share of Class B Common Stock is issued for each common unit of Medline Holdings, LP ("Common Units") held. Upon an exchange of Common Units for shares of the Issuer's Class A common stock ("Class A Common Stock"), an equivalent number of shares of Class B Common Stock held by such holder will be automatically cancelled.
Footnote F3
Represents a grant of restricted stock units ("RSUs"), of which 25% vest on June 15, 2026 and the remaining 75% vest in three equal annual installments beginning on March 1, 2027.
Footnote F4
Pursuant to the terms of an exchange agreement, dated as of December 16, 2025 (the "Exchange Agreement"), holders have the right to exchange their Common Units for shares of the Class A Common Stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire. Such Common Units are held indirectly through Medline Management Aggregator LLC.
Footnote F5
Reflect incentive units of Medline Holdings, LP ("Incentive Units"), which are "profit interests" having economic characteristics similar to stock appreciation rights. Vested Incentive Units are convertible, at the holder's election, into a number of Common Units generally equal to (a) the product of the number of vested Incentive Units to be converted with a given per unit participation threshold and then-current difference between the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock) and the per unit participation threshold of such vested Incentive Units divided by (b) the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock), subject to certain adjustments.
Footnote F6
(Continued from Footnote 5 above) Common Units are exchangeable on a one-for-one basis for shares of Class A Common Stock pursuant to the terms of the Exchange Agreement. These Incentive Units have no expiration date. Such Incentive Units are held indirectly through Medline Management Aggregator LLC.
Footnote F7
70% of these Incentive Units have vested, and the remaining 30% vest on October 21, 2026.
Footnote F8
These Incentive Units are fully vested.
Footnote F9
40% of these Incentive Units have vested, and the remaining 60% vest in three equal annual installments beginning on April 1, 2026.
Footnote F10
20% of these Incentive Units have vested, and the remaining 80% vest in four equal annual installments beginning on March 29, 2026.
Footnote F11
These Incentive Units vest in five equal annual installments beginning on March 28, 2026.
Footnote F12
These securities are held by a trust, of which the Reporting Person is a trustee.